Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies

NCT04748185 · clinicaltrials.gov ↗

COMPLETED

Status

358

Enrollment

OTHER

Sponsor class

Conditions

Monoclonal B-Cell Lymphocytosis
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
B-cell Non Hodgkin Lymphoma
Hodgkin Lymphoma

Sponsor

Mayo Clinic